Trial · NCT03176771
Adverse events255
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
81 to 100 of 255
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Suicidal ideation | Psychiatric disorders | Placebo (Double-Blind Placebo-Controlled Period) | 0 | 84 | |
| other | Suicidal ideation | Psychiatric disorders | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | 1 | 85 | |
| other | Suicidal ideation | Psychiatric disorders | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | 0 | 84 | |
| other | Suicidal ideation | Psychiatric disorders | MT-5199 40 mg (Double-Blind Extension Period) | 6 | 108 | |
| other | Suicidal ideation | Psychiatric disorders | MT-5199 80 mg (Double-Blind Extension Period) | 3 | 95 | |
| serious | Myocardial ischaemia | Cardiac disorders | Placebo (Double-Blind Placebo-Controlled Period) | 0 | 84 | |
| serious | Myocardial ischaemia | Cardiac disorders | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | 0 | 85 | |
| serious | Myocardial ischaemia | Cardiac disorders | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | 0 | 84 | |
| serious | Myocardial ischaemia | Cardiac disorders | MT-5199 40 mg (Double-Blind Extension Period) | 1 | 108 | |
| serious | Myocardial ischaemia | Cardiac disorders | MT-5199 80 mg (Double-Blind Extension Period) | 0 | 95 | |
| serious | Death | General disorders | Placebo (Double-Blind Placebo-Controlled Period) | 0 | 84 | |
| serious | Death | General disorders | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | 0 | 85 | |
| serious | Death | General disorders | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | 0 | 84 | |
| serious | Death | General disorders | MT-5199 40 mg (Double-Blind Extension Period) | 1 | 108 | |
| serious | Death | General disorders | MT-5199 80 mg (Double-Blind Extension Period) | 1 | 95 | |
| serious | Fatigue | General disorders | Placebo (Double-Blind Placebo-Controlled Period) | 0 | 84 | |
| serious | Fatigue | General disorders | MT-5199 40 mg (Double-Blind Placebo-Controlled Period) | 0 | 85 | |
| serious | Fatigue | General disorders | MT-5199 80 mg (Double-Blind Placebo-Controlled Period) | 0 | 84 | |
| serious | Fatigue | General disorders | MT-5199 40 mg (Double-Blind Extension Period) | 1 | 108 | |
| serious | Fatigue | General disorders | MT-5199 80 mg (Double-Blind Extension Period) | 0 | 95 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03176771/events?page=5